ALDEYRA THERAPEUTICS INC's ticker is ALDX and the CUSIP is 01438T106. A total of 73 filers reported holding ALDEYRA THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 1.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $125 | -18.3% | 18,684 | +2.7% | 0.00% | – |
| Q2 2023 | $153 | -84.7% | 18,200 | +4818.9% | 0.00% | – |
| Q2 2022 | $1,000 | -99.3% | 370 | -98.9% | 0.00% | – |
| Q1 2022 | $143,000 | +10.9% | 32,203 | 0.0% | 0.00% | – |
| Q4 2021 | $129,000 | -54.6% | 32,203 | -0.4% | 0.00% | – |
| Q3 2021 | $284,000 | -39.6% | 32,332 | -22.1% | 0.00% | – |
| Q2 2021 | $470,000 | +993.0% | 41,500 | +135.8% | 0.00% | – |
| Q1 2020 | $43,000 | -57.8% | 17,600 | 0.0% | 0.00% | – |
| Q4 2019 | $102,000 | +9.7% | 17,600 | 0.0% | 0.00% | – |
| Q3 2019 | $93,000 | -12.3% | 17,600 | 0.0% | 0.00% | – |
| Q2 2019 | $106,000 | -33.3% | 17,600 | 0.0% | 0.00% | – |
| Q1 2019 | $159,000 | +8.9% | 17,600 | 0.0% | 0.00% | – |
| Q4 2018 | $146,000 | -39.9% | 17,600 | 0.0% | 0.00% | – |
| Q3 2018 | $243,000 | +73.6% | 17,600 | 0.0% | 0.00% | – |
| Q2 2018 | $140,000 | – | 17,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 1,400,239 | $6,224,000 | 4.02% |
| Tri Locum Partners LP | 1,447,445 | $6,434,000 | 2.51% |
| Knoll Capital Management, LLC | 759,405 | $3,376,000 | 2.12% |
| Perceptive Advisors | 9,903,879 | $44,023,000 | 0.88% |
| JOHNSON & JOHNSON | 394,834 | $1,755,000 | 0.33% |
| APOGEM CAPITAL LLC | 104,042 | $462,000 | 0.32% |
| Ikarian Capital, LLC | 375,000 | $1,667,000 | 0.22% |
| 683 Capital Management, LLC | 500,000 | $2,223,000 | 0.12% |
| Verition Fund Management LLC | 2,105,907 | $9,361,000 | 0.11% |
| Palo Alto Investors LP | 160,800 | $715,000 | 0.06% |